Tobacco gets new, healthy image

Tobacco use triggers a number of common diseases in humans including heart disease and lung cancer. However, a group of scientists from Europe may be tobacco's saving grace. They successfully used genetically modified tobacco plants to generate medicines for a number of autoimmune and inflammatory diseases. The study was part of the Pharma-Planta project, which was funded under the EU's Sixth Framework Programme (FP6) to the tune of EUR 12 million. The study's results were recently published in the open access journal BMC Biotechnology.

The scientists targeted the creation of transgenic tobacco plants with the capacity to generate biologically-active interleukin-10 (IL-10), a small protein known as a cytokine that regulates the immune system.

Led by Professor Mario Pezzotti from the University of Verona in Italy, the team tested two different versions of IL-10 (viral and murine) and produced plants in which this protein was targeted to three different compartments within the cell in order to assess the most effective one.

The researchers noted that oral administration of this cytokine alone, or in combination with disease-associated autoantigens, could offer protection from the onset of a specific autoimmune disease through the 'induction of oral tolerance'.

Furthermore, the team found that the tobacco plants successfully processed both forms of IL-10. Active cytokine was produced at high enough levels making it possible to use tobacco leaves without wasting a lot of time for extraction or purification. Transgenic plants are able to increase proportionally at low cost and with low maintenance.

"The fact that they can be eaten, which delivers the drug where it is needed, thus avoiding lengthy purification procedures, is another plus compared with traditional drug synthesis," explained Professor Pezzotti. "These results clearly demonstrate that tobacco plants can express the viral and murine IL-10 genes, process and assemble the corresponding proteins into functional, biologically-active dimers," he added.

The scientists are eager to use the plants to determine whether repeated small doses could help prevent type 1 diabetes mellitus (T1DM), in combination with other auto-antigens associated with the disease. They have set their sights on the 65-kDa isoform of the enzyme glutamic acid decarboxylase (GAD65) for the testing.

"The accumulation levels of both viral and murine IL-10 in tobacco leaves are high enough to provide sufficient material for oral administration in oral tolerance studies using the available mouse models," Professor Pezzotti said.

"This study paves the way to performing feeding studies in mouse models of autoimmune diseases, which will allow the evaluation of the immunomodulatory properties and effectiveness of the viral IL-10 in inducing oral tolerance compared to the murine protein."

Collaborating with the University of Verona were the Institute for Molecular Biotechnology (Germany), Fraunhofer Institute for Molecular Biology and Applied Ecology (Germany), Max-Planck-Institute of Molecular Plant Physiology (Germany), the University of Natural Resources and Applied Life Sciences (Austria) and the University of Perugia (Italy).

For further information, please visit:

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Unusual type of antibody shows ultrapotent activit…

An unusual type of antibody that even at miniscule levels neutralizes the Zika virus and renders the virus infection undetectable in preclinical models has been identifie...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...